Novetron (Ondansetron)

Ondansetron, the active ingredient in Novetron, is a 5‑HT3 receptor antagonist presented as an oral formulation for oral use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery in adult patients. The product conforms to European Union regulatory standards and is available by prescription.

GNH USA supplies Novetron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, ensuring reliable quality and timely delivery. Our global network supports regulatory compliance and logistics coordination for international shipments.

Novetron (ondansetron) is used to control nausea and vomiting mediated by serotonin pathways in several clinical settings.

Chemotherapy-induced nausea and vomiting: reduces acute and delayed episodes in patients receiving emetogenic cancer therapy. Radiotherapy-induced nausea and vomiting: helps control nausea associated with radiation treatment. Postoperative nausea and vomiting: prevents and treats nausea and vomiting after surgical procedures.

Common Side Effects: - Headache: mild to moderate pain often reported. - Constipation: reduced bowel movements. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools. - Abdominal pain: mild discomfort.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmia. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Serotonin syndrome: agitation, hyperthermia when combined with other serotonergic drugs. - Cardiac arrhythmias: irregular heartbeat. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Novetron, consider the following precautions.

Assess cardiac risk: evaluate QT interval and correct electrolyte abnormalities. Monitor electrolytes: treat hypokalaemia or hypomagnesemia before use. Use with caution in hepatic impairment: dose adjustment may be required. Avoid concomitant use with other QT‑prolonging agents unless benefits outweigh risks. Pregnancy and lactation: discuss potential risks with the prescriber; data are limited. Store at room temperature: keep in the original container, protect from moisture and light.

Novetron may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Other QT‑prolonging drugs (e.g., quinidine, haloperidol): increased risk of arrhythmia. - Apomorphine: may cause severe hypotension. - Serotonergic agents (e.g., tramadol) combined with ondansetron may raise serotonin syndrome risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce effectiveness. - Aprepitant: may require dose adjustment of ondansetron.